
Molecular Pharmacology Program
The David Scheinberg Lab
Research

Professor
The overall goals of this laboratory are to develop novel targeted immunotherapies based on effectors of the immune system and to understand their mechanisms of action as well as the mechanisms of resistance to them. This includes antibodies, targeted nano-devices, engineered cells, and active specific agents such vaccines. An important goal is to take these new therapies into human clinical trials for testing. Examples include a molecular nanogenerator that releases alpha particles inside cancer cells, now being tested in Phase II human trials (Blood, 2010), and a vaccine to WT1 in Phase III trials. Read full article in Science.
We have developed targeted alpha particle therapies, targeted beta emitters, oncogenic protein peptide vaccines, humanized antibodies, each of which reached human clinical trials; More recently we have discovered TCR mimic antibodies to intracellular proteins (Science Trans. Med., 2013), (Nature Biotech., 2015), as well as prototype targeted nano-machines (Nature Nano, 2013), and cellular micropharmacies (Nature Chem.Biol., 2021).
Research Projects

Featured News


Publications
Dao T, Pankov D, Scott A, Korontsvit T, Zakhaleva V, Xu Y, Xiang J, Yan S, de Morais Guerreiro MD, Veomett N, Dubrovsky L, Curcio M, Doubrovina E, Ponomarev V, Liu C, O’Reilly RJ, Scheinberg DA. Therapeutic bispecific T-cell engager antibody targeting the intracellular oncoprotein WT1. Nature biotechnology. 2015;33(10):1079-86. Doi: 10.1038/nbt.3349. PubMed PMID: 26389576; PMCID: PMC4600043.
People

David A. Scheinberg, MD, PhD
Chair, Center for Experimental Therapeutics, MSK; Deputy Director, Sloan Kettering Institute, for Therapeutic Discovery
Professor
- Molecular Pharmacology Program Member David Scheinberg focuses on the discovery and development of novel, specific immunotherapeutic agents and targeted nanodevices for cancer therapy.
- MD, PhD, Johns Hopkins University School of Medicine
- [email protected]
- Email Address
- 646-888-2190
- Office Phone
- View physician profile
- Physician profile
Members


- PhD: Immunology, Hyogo College of Medicine, Japan
- MD: Medicine, Medical School of Inner Mongolia
- Postdoctoral: Immunology, Yale Medical School Immunobiology.


- PhD in Chemistry from Case Western Reserve University in Cleveland, Ohio (1985)
- ME in Chemical Engineering from The City University of New York (2004)

- BS in Biophysics from Humboldt University in Berlin (2018)
- MS in Biomedical Sciences from UCL London (2019)

- BA in Biology from Swarthmore College, Swarthmore, PA (2017)


- PhD in Oncology from A. C. Camargo Hospital, Sao Paulo, BR
- and from MD Anderson Cancer Center, Texas US (2009)

- MD, Weill Cornell Medicine College, (2015)
- BA Neuroscience, The Johns Hopkins University, (2007)

- BS in Pharmacology, MA in Molecular Biology, University of California, Santa Barbara

- MD from University of Central Florida College of Medicine, 2016


- PhD in Immunology from Heinrich Heine University, Germany (2015)


- BS in Biochemistry and Molecular Biology from The University of Georgia, Athens, GA, 2018

- MD in Internal Medicine from Sechenov (1st) Moscow Medical Institute, Moscow, Russia,(1990)
- PhD in Medical Science, from State Scientific Center of Russian Federation Institute of Biophysics, Moscow, Russia,(1997)

- BS in Biomedical Engineering from UC San Diego, CA (2012)
- MEng. in Biomedical Engineering from Cornell University (2013)

- BS in Chemistry from The College of New Jersey, Ewing NJ (2019)

- MSc in Molecular Biotechnology from Ruprecht-Karls University of Heidelberg, Germany, 2021
- BSc in Molecular Biotechnology from Ruprecht-Karls University of Heidelberg, Germany, 2017

Research Assistant

Senior Research Scientist

Research Assistant

Laboratory Member

Graduate Student

Graduate Student

Graduate Student

Research Assistant

Research Associate

Graduate Student

Pediatric Hematology/Oncology Fellow

Hematology/Oncology Fellow

Senior Research Scientist

Research Technician

Graduate Student

Senior Research Scientist

Graduate Student

Graduate Student

Graduate Student

- BS, Cornell University




- BS in Biomedical Engineering from Boston University (2016)


- MD from Eberhard Karls University in Tuebingen, Germany (2014)

- BS in Biology from St. John' s University in Queens, NY (2017)

- PhD in Chemistry from Tufts University (2018)
- BS in Biochemistry from Hobart and William Smith Colleges (2013)
Lab Alumni

Principal Scientific Communication Lead at Genentech, San Francisco, CA

Graduate Student


Research Fellow

Graduate Student
Graduate Student

Visiting Scientist
Graduate Student
Research Technician
Graduate Student
Graduate Student
Graduate Student
Graduate Student

Research Technician

Research Technician

Lab Rotation SEP-DEC 2020

Graduate Student

Research Technician

Graduate Student

Research Fellow

Research Fellow

Research Assistant

Research Scholar
Lab Affiliations
- Molecular Pharmacology Program
- Department of Medicine
- Center for Experimental Therapeutics
- Center for Cell Engineering
- Geoffrey Beene Cancer Research Center
- Center for Molecular Imaging & Bioengineering
- Tri-Institutional PhD Program in Chemical Biology
- Gerstner Sloan Kettering Graduate School of Biomedical Sciences
Lab News & Events
Journal Club & Photo AlbumGet in Touch
-
Lab Head Email
-
Office Phone
-
Lab Phone
Lab Resources
To learn more about Postdoc compensation and benefits at MSK, please visit https://www.mskcc.org/education-training/postdoctoral/resources-postdocs/compensation-benefits-resources
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
David A. Scheinberg discloses the following relationships and financial interests:
-
Actinium
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services -
Arvinas, Inc.
Ownership / Equity Interests -
Bridge Medicines
Provision of Services (uncompensated) -
CoImmune, Inc.
Intellectual Property Rights; Ownership / Equity Interests; Provision of Services -
Ensysce Bioscience
Ownership / Equity Interests -
Eureka Therapeutics Inc
Ownership / Equity Interests; Provision of Services (uncompensated) -
Great Point Partners
Ownership / Equity Interests; Provision of Services
-
Iovance Biotherapeutics, Inc.
Ownership / Equity Interests -
Lantheus Medical Imaging, Inc.
Ownership / Equity Interests -
OncoPep, Inc.
Provision of Services -
Pfizer, Inc.
Ownership / Equity Interests; Provision of Services -
Repertoire Immune Medicines, Inc.
Provision of Services -
Sapience Therapeutics, Inc.
Fiduciary Role/Position; Ownership / Equity Interests -
Sellas Life Science Group
Fiduciary Role/Position; Intellectual Property Rights; Ownership / Equity Interests
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].